A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study was to study the effects of donepezil on cognition in patients with schizophrenia. The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central South University
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• DSM-IV diagnosis of schizophrenia as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version;

• Between 18 and 40 years of age;

• Duration of the illness must be longer than 2 year;

• Patient's current antipsychotic medication regimen must be stable;

• Must be in a stable living arrangement;

Exclusion Criteria:

• Patient has mental retardation or severe organic brain syndromes;

• Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening;

• Has suicidal attempts or ideation or violent behavior within the last 12 months;

• Patient has a history of alcohol/drug dependence;